March 13th 2024
Federico Cappuzzo, MD, discusses the clinical significance of the RATIONALE-315 trial of perioperative tislelizumab in non–small cell lung cancer.
March 11th 2024
Susan C. Modesitt, MD, FACOG, FACS, sheds light on the latest research with antibody-drug conjugates across gynecologic cancers.
Arndt Vogel, MD, discusses the importance of multidisciplinary tumor boards in navigating the treatment arsenal in advanced hepatocellular carcinoma.
March 6th 2024
March 5th 2024
Michael J. Overman, MD, discusses the potential use of endoscopy and ctDNA assays to guide nonoperative approaches in select gastrointestinal cancers.
March 4th 2024
Michael J. Overman, MD, discusses the potential advantages of using nonoperative immunotherapy-based approaches in select gastrointestinal cancers.
SpringWorks Therapeutics has initiated a new drug application for mirdametinib in neurofibromatosis type 1-associated plexiform neurofibromas.
February 29th 2024
Robert S. Negrin, MD, discusses the use of Orca-T as a viable strategy for patients with hematologic malignancies undergoing allogeneic transplant.
February 28th 2024
Nikhil A. Gopal, MD, discusses the benefit of belzutifan in addition to effective immunotherapy-based regimens in advanced RCC.
February 27th 2024
Daniel Olson, MD, discusses the significance of the FDA approval of lifileucel for patients with advanced melanoma.
February 26th 2024
BAY 2927088 has received breakthrough therapy designation by the FDA for pretreated non–small cell lung cancer harboring activating HER2 mutations.
Jacob Shreve, MD, MS, highlights the intersection between artificial intelligence and personalized medicine, as well as its potential utility in gastrointestinal cancers.
February 23rd 2024
Luspatercept has been recommended for approval by the EMA for patients with transfusion-dependent anemia and lower-risk myelodysplastic syndromes.
Early data seen with acalabrutinib plus axi-cel indicate the combination’s feasibility as bridging therapy in relapsed/refractory B-cell lymphoma.
February 21st 2024
David A. Sallman, MD, discusses the potential use of fedratinib to manage symptomatic myelodysplastic syndrome/myeloproliferative neoplasms.
Tatyana Feldman, MD, highlights updated data for liso-cel in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
February 19th 2024
Following chemoradiation, maintenance osimertinib improved PFS vs placebo in patients with stage III EGFR-mutant non–small cell lung cancer.
Jane L. Meisel, MD, discusses the importance of prioritizing patients’ toxicity concerns and quality of life in the management of breast cancer.
Jobelle Baldonado, MD, highlights the emergence of targeted therapies and the need for reflex-ordered molecular testing in early-stage lung cancer.
February 15th 2024
Matthew Galsky, MD, discusses the significance of the FDA approval of enfortumab vedotin plus pembrolizumab as a first-line regimen in urothelial cancer.